Angeion begins European trials of Sentinel 2010:
This article was originally published in Clinica
Angeion has begun clinical evaluation of its Sentinel 2010 implantable cardioverter defibrillator. The first device was implanted in a patient in the Czech Republic. The 60 cc 2010 series weighs 110 g and stores 5.5 minutes of ECG. It is based on the Sentinel 2000, which is currently in US clinical trials and has been audited for CE marking by TUV Product Services of Munich, Germany.
You may also be interested in...
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.
The US FDA wants manufacturers and compounding facilities to test drug products for methanol in alcohol ingredients, and responds to reports of fatal methanol poisonings of consumers who ingested alcohol-based based hand sanitizers.